Berenberg Bank Reiterates “Buy” Rating for Hikma Pharmaceuticals (LON:HIK)

Hikma Pharmaceuticals (LON:HIK)‘s stock had its “buy” rating reissued by Berenberg Bank in a report released on Thursday,Digital Look reports. They currently have a GBX 2,300 target price on the stock. Berenberg Bank’s price objective would suggest a potential upside of 48.96% from the stock’s previous close.

A number of other research firms have also recently commented on HIK. Jefferies Financial Group reissued a “buy” rating and set a GBX 2,360 target price on shares of Hikma Pharmaceuticals in a research report on Friday, November 7th. Deutsche Bank Aktiengesellschaft dropped their price target on shares of Hikma Pharmaceuticals from GBX 2,500 to GBX 2,400 and set a “buy” rating on the stock in a research note on Friday, January 9th. JPMorgan Chase & Co. decreased their price objective on shares of Hikma Pharmaceuticals from GBX 2,500 to GBX 2,400 and set an “overweight” rating for the company in a research report on Friday, November 7th. Finally, Peel Hunt reiterated a “buy” rating and issued a GBX 2,170 price target on shares of Hikma Pharmaceuticals in a research note on Friday, November 7th. Five research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Hikma Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of GBX 2,326.

Hikma Pharmaceuticals Stock Performance

Hikma Pharmaceuticals stock opened at GBX 1,544 on Thursday. The firm has a market capitalization of £3.42 billion, a PE ratio of 9.25, a price-to-earnings-growth ratio of 2.38 and a beta of 0.41. Hikma Pharmaceuticals has a one year low of GBX 1,482 and a one year high of GBX 2,360. The stock’s 50 day moving average price is GBX 1,551.96 and its 200 day moving average price is GBX 1,711.93. The company has a debt-to-equity ratio of 55.82, a quick ratio of 1.27 and a current ratio of 1.66.

Insider Transactions at Hikma Pharmaceuticals

In other news, insider Said Darwazah purchased 70,000 shares of the firm’s stock in a transaction that occurred on Friday, November 7th. The stock was acquired at an average cost of GBX 1,541 per share, for a total transaction of £1,078,700. Also, insider Mazen Darwazah acquired 315,000 shares of the stock in a transaction that occurred on Thursday, November 6th. The stock was purchased at an average cost of GBX 1,601 per share, with a total value of £5,043,150. Over the last 90 days, insiders have purchased 448,214 shares of company stock valued at $712,497,058. Insiders own 18.15% of the company’s stock.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 800+ (as of Feb 2025) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.